PsA Secukinumab XCT Structural Progression Study

Sponsor
Chinese University of Hong Kong
Study ID
NCT03623867
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
  • Placebo — DRUG
    Subject will take placebo once weekly in week 0-4, and once monthly till week 48

Study Details

Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment pathway through anti IL-17 gives promising clinical improvement. Yet, its effect on radiographic progression remains uncertain. This study aimed to ascertain the effect of secukinumab on structural progression in PsA by evaluation through high resolution peripheral quantative computed tomography (HRpqCT).

Key Dates

Start date
May 18, 2020
Status verified
Sep 2023
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab
    Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
  • Placebo Comparator: Placebo
    Subject will received placebo 150mg at week 0-4, and once monthly till week 48

Primary Outcome Measure

Difference in changes in the volume of erosions on metacarpophalangeal joints (MCP) 2-4 measured by HR-pQCT at 24 weeks between secukinumab and placebo group [ Time Frame: 24 weeks ]

Related Studies